Market Place
Sourcing Support
Immunomic Doses First Patient in its Phase 1 Clinical Trial of ITI-1001
24 Aug 2023 //
BUSINESSWIRE
Immunomic Announces Presentation on Manufacturing Cell Therapies at Summit 2023
06 Mar 2023 //
BUSINESSWIRE
PharmaJet Partner Immunomic Receive FDA Fast Track Designation for pDNA Vaccine
13 Dec 2022 //
BUSINESSWIRE
US FDA grants fast track designation to Immunomic Therapeutics’ pDNA vaccine
10 Nov 2022 //
PHARMABIZ
Immunomic Receives FDA Fast Track Designation for ITI-3000
08 Nov 2022 //
WVNEWS
Immunomic Therapeutics Appoints Vice President, Cell Therapy
07 Jun 2022 //
BUSINESSWIRE
Immunomic Announces Clinical Trial of ITI-3000 for Merkel Cell Carcinoma
07 Feb 2022 //
BUSINESSWIRE
Immunomic Therapeutics Announces Collaboration With iOncologi
23 Nov 2021 //
BUSINESSWIRE
Immunomic Presents Data From ATTAC Studies in GBM at 2021 SNO
18 Nov 2021 //
BUSINESSWIRE
Immunomic Therapeutics Expands Board of Directors with Two New Members
27 Jul 2021 //
PR NEWSWIRE
Immunomic Collaborator Dr. John Sampson Recognized as “World Expertâ€
21 Jul 2021 //
BUSINESSWIRE
Immunomic Strengthens Leadership Team with Appointment of Robert Newman
19 Jul 2021 //
BUSINESSWIRE
Immunomic Announces License Agreement With Lineage Cell Therapeutics
19 Apr 2021 //
BUSINESSWIRE
Lineage Announces Worldwide License Agreement With Immunomic Therapeutics
19 Apr 2021 //
BUSINESSWIRE
Immunomic Therapeutics Executives and Board Members of WhyWeVax™
09 Dec 2020 //
BUSINESSWIRE
Immunomic Therapeutics to Present at The (SITC) 35th Anniversary
02 Nov 2020 //
BLOOMBERG
Immunomic Therapeutics’ CEO to be at Bio Innovation Conference Meeting 2020
29 Sep 2020 //
BUSINESSWIRE
Immunomic Therapeutics Announces Results of CMV-Specific Dendritic Cell Vaccines
01 Sep 2020 //
BUSINESSWIRE
Immunomic Therapeutics Announces Results from 3 ATTAC Studies
01 Sep 2020 //
BUSINESSWIRE
Immunomic Therapeutics Announces Publication of Results from 3 ATTAC Studies
31 Aug 2020 //
BUSINESSWIRE
Replicate Bioscience and Immunomic Therapeutics Form Collaboration
24 Jun 2020 //
BUSINESSWIRE
Immunomic Therapeutics Enters into License Agreement with Ichor Medical Systems
16 Jun 2020 //
BUSINESSWIRE
Immunomic Enters into License Agreement with Ichor Medical to Use (EP) ITI-1001
16 Jun 2020 //
BUSINESSWIRE
Immunomic Therapeutics to Present at AACR Virtual Annual Meeting II
11 Jun 2020 //
BUSINESSWIRE
Immunomic Therapeutics Announces Appointments to its Board of Directors
05 May 2020 //
BUSINESSWIRE
Immunomic partners EpiVax and PharmaJet on Covid-19 vaccine
13 Apr 2020 //
PHARMACEUTICAL-TECHNOLOGY
Immunomic Therapeutics Forms Collaboration with EpiVax and PharmaJet
09 Apr 2020 //
YAHOO
Immunomic`s Announces Completion of Pre-IND Meeting with US FDA for ITI-1001
03 Mar 2020 //
BUSINESSWIRE
University of Florida Presents New Clinical Data from ATTAC-II Study
21 Nov 2019 //
BIO SPACE
